TPST stock forecast, quote, news & analysis
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity... Show more
Why Tempest Therapeutics (TPST) Stock Is Down -51% in the Last 30 Days
Key Takeaways
- TPST fell roughly 51% over the last 30 days, sliding from about $0.77 to approximately $0.38 per share as of early November 2026.
- The decline largely reflects a sharp reversal after September's high-volume spike, with dilution, financing, and listing risks weighing on sentiment.
- On November 4, 2026, Tempest disclosed a Nasdaq minimum bid price deficiency notice after its stock closed below $1.00 for 30 consecutive business days.
- The company also announced a CFO transition in late October, adding leadership uncertainty during a pivotal financing period.
- Over the broader quarter, the stock has retreated more than 60% from its mid-August levels near $1.00–$1.10.
- Investors continue to watch pipeline milestones for the in vivo CAR-T candidates TPST-4003 and TPST-2003 alongside the company's capital position.
- For additional detail, explore Tempest's Price Targets, Earnings, and Forecast pages.
- Discover data-driven trading ideas in Tickeron's Trending AI Robots section.
Tempest Therapeutics (TPST) Company Overview and Market Position
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California, focused on developing next-generation in vivo CAR-T therapies for oncology and autoimmune disease. The company's lead program, TPST-4003, combines a dual-targeting CD19/BCMA CAR structure with a proprietary CD7-targeted mRNA/LNP delivery system intended to enable broad "immune reset" across multiple indications. Tempest also continues to advance TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy being evaluated in relapsed/refractory multiple myeloma through partner-sponsored trials.
Because Tempest is pre-revenue and relies heavily on equity financings and strategic partnerships, investors follow the stock closely for clinical data readouts, partnership announcements, and balance-sheet updates rather than traditional earnings metrics.
Tempest Therapeutics (TPST) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TPST declined approximately 51%, moving from a closing price near $0.77 in early October to about $0.38 by early November. The move was not linear: the stock briefly firmed in late September before a steady slide through October that accelerated into November.
The quarterly picture is even steeper. From mid-August levels of roughly $1.00 to $1.10, the stock has fallen more than 60%, reflecting sustained selling pressure that followed an outsized but short-lived rally in mid-September.
What Drove TPST Stock Price in the Last 30 Days
The most significant near-term pressure came from financing and listing concerns. On November 4, 2026, Tempest disclosed that Nasdaq had issued a minimum bid price deficiency notice because the stock had closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, and the company has until May 3, 2027 to regain compliance, but it underscored the market's concerns about the company's capital position and potential dilution.
Leadership changes also contributed to uncertainty. In late October, Tempest announced that Chief Financial Officer Constance Ames resigned for personal reasons, with the board appointing Stephanie Horn-Warnock as CFO effective immediately. The rapid finance-function transition arrived at a time when investors were already focused on the company's liquidity and runway.
These developments followed September's dramatic volatility. On September 16, the stock surged on very heavy volume after Tempest announced an exclusive option agreement with Hebei Senlang Biotechnology related to its in vivo CAR-T platform, and later that month it signed a related-party Master Services Agreement with Factor Bioscience covering research and development services. The gains quickly faded, however, as profit-taking and broader concerns about share structure and dilution took hold.
What Drove TPST Stock Performance Over the Last Quarter
The quarterly decline reflects a larger narrative of a small, pre-revenue biotech navigating capital constraints while advancing an early-stage pipeline. After the February 2026 asset acquisition from Factor Bioscience and Erigen LLC brought in new CAR-T assets, Tempest has focused on disciplined capital deployment and partnerships to fund development. However, the company ended recent quarters with modest cash balances, leaving it dependent on additional financings that can pressure the share price.
Corporate-governance friction also played a role. Tempest repeatedly adjourned and reconvened a special stockholder meeting through mid-October seeking approval to amend its charter and permit stockholder action by written consent, a process that highlighted an evolving shareholder base and voting dynamics. Combined with the Nasdaq deficiency notice, these factors have kept sentiment subdued even as the company works toward first-in-human milestones for TPST-4003.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing and most relevant AI-powered trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the bots demonstrating the strongest recent performance and relevance are featured in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, giving traders a range of approaches to explore. For investors seeking data-driven, systematic perspectives on names like TPST and the broader market, this section provides a convenient starting point to review active bot strategies.
TPST Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors should monitor several factors. First is the company's path back to Nasdaq compliance, including any capital-raising activity that could affect the share count and price. Second, pipeline progress for TPST-4003, including planned first-in-human dosing and initial clinical data expectations, and continued TPST-2003 development toward a potentially registrational study in multiple myeloma will be key catalysts. Third, quarterly financial disclosures will be scrutinized for cash balance, runway, and any new partnership or licensing announcements. Finally, broader biotech financing conditions and sector sentiment will likely influence a stock that remains highly sensitive to liquidity and dilution dynamics. This information is provided for general purposes and is not a recommendation to buy or sell any security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TPST turns negative, indicating new downward trend
TPST saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 73 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TPST turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TPST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPST advanced for three days, in 178 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TPST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.897) is normal, around the industry mean (3.498). P/E Ratio (-0.103) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. TPST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals
Industry Biotechnology